# The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema

> **NCT05003453** · PHASE2,PHASE3 · COMPLETED · sponsor: **RDC Clinical Pty Ltd** · enrollment: 72 (actual)

## Conditions studied

- Eczema, Atopic

## Interventions

- **DRUG:** 1.5% Palmitoylethanolamide (PEA) sold as Levagen+
- **DRUG:** Placebo Comparator

## Key facts

- **NCT ID:** NCT05003453
- **Lead sponsor:** RDC Clinical Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-29
- **Primary completion:** 2022-06-03
- **Final completion:** 2022-06-30
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05003453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05003453, "The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05003453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*